

# Thoracic Disease-Oriented Team

---

Clinical Research Treatment Flowchart



## ADVANCED/METASTATIC

■ Open to Accrual

■ Low Accruing

■ Pending Activation

1L

**UCI 24-192 (Nuvalent)**  
 NVL-655 vs Alectinib

Mechanism: ALK inhibitor  
 Coord: Mindy Chen  
 PI: Dr. Nagasaka  
 Accrual: 1/5

2L

**UCI 21-241 (Nuvalent)**  
 NVL-655 + ALK inhibitor

Mechanism: ALK Inhibitor  
 Coord: Keagan Buttigieg  
 PI: Dr. Nagasaka  
 Accrual: 20/25

**UCI 25-51 (Nuvalent)**  
 NVL-655 EAP

Mechanism: ALK inhibitor  
 Coord: Mindy Chen  
 PI: Dr. Park  
 Accrual: 11/20

**UCI 25-189 (Astellas)**

Mechanism: ALK inhibitor  
 Coord: To be determined  
 PI: Dr. Arter  
 Accrual: 0/5

**UCI 26-23 (Triana Biomedicines)**

Mechanism: ALK inhibitor  
 Coord: To be determined  
 PI: Dr. Nagasaka  
 Accrual: 0/10

Exon 18

Exon 19 del or L858R

1L

2L

**UCI 24-169**  
**(BlossomHill Therapeutics)**  
 BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
 Coord: Celest Ramirez  
 PI: Dr. Nagasaka  
 Accrual: 11/15

**UCI 24-169**  
**(BlossomHill Therapeutics)**  
 BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
 Coord: Celest Ramirez  
 PI: Dr. Nagasaka  
 Accrual: 11/15

**UCI 24-181**  
**(Janssen Research & Development)**  
 Amivantamab + Lazertinib  
 Mechanism: EGFR TKI  
 Coord: Stephanie Fernandez  
 PI: Dr. Park  
 Accrual: 4/10

**UCI 23-178**  
 BL-B01D1 IV  
 Mechanism: EGFR and/or HER3 bispecific antibody  
 Coord: Cassie Smith  
 PI: Dr. Park  
 Accrual: 5/10

**UCI 22-217**  
**(Janssen)**  
 Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI and Chemo  
 Coord: Richard Chang  
 PI: Dr. Nagasaka  
 Accrual: 5/15

**UCI 25-80**  
**(AstraZeneca/TROPION-Lung14)**  
 Osimertinib +/- Dato-DXd  
 Mechanism: TKI +/- ADC  
 Coord: TBD  
 PI: Dr. Nagasaka  
 Accrual: 0/5

**UCI 25-187**  
**(BMS/IZABRIGHT-Lung01)**  
 Iza-Bren vs platinum based chemo + pemetrexed  
 Mechanism: ADC  
 Coord: TBD  
 PI: Dr. Nagasaka  
 Accrual: 0/5



Exon 20

Exon 21

1L

**UCI 22-217 (Janssen)**  
 Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI and Chemo  
 Coord: Richard Chang  
 PI: Dr. Nagasaka  
 Accrual: 5/15

**UCI 24-169 (BlossomHill Therapeutics)**  
 BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
 Coord: Celest Ramirez  
 PI: Dr. Nagasaka  
 Accrual: 11/15

**UCI 24-169 (BlossomHill Therapeutics)**  
 BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
 Coord: Celest Ramirez  
 PI: Dr. Nagasaka  
 Accrual: 11/15

**UCI 24-181 (Janssen Research & Development)**  
 Amivantamab + Lazertinib  
 Mechanism: EGFR TKI  
 Coord: Stephanie Fernandez  
 PI: Dr. Park  
 Accrual: 4/10

2L



Exon 20 / Uncommon and Compounded Mutations

1L

UCI 26-10 (UCLA/L-13)  
Zipalertinib with Carboplatin +  
Pemetrexed

Mechanism: TKI + Chemo  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5

2L



## ADVANCED/METASTATIC

Exon 18

Exon 19

Exon 20

Exon 21

1L

UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI

Coord: Celest Ramirez

PI: Dr. Nagasaka

Accrual: 11/15

2L

UCI 23-178

BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody


Coord: Cassie Smith

PI: Dr. Park

Accrual: 5/10



## Early Stage

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-79 (Beamion Lung-3)  
Zongertinib vs SOC

Mechanism: TKI  
Coord: To be determined  
PI: Dr. Arter  
Accrual: 0/3

KRAS G12C

G12A, G12D, G12R, G12S, G12V (Cont.)

1L

UCI 22-30 (D3S-001-100):  
D3 Bio

Mechanism: TKI  
Coord: Cassie Smith  
PI: Dr. Nagasaka  
Accrual: 5/8

UCI 25-88 (Part A:  
Olomorasib w/ Pembro or  
Placebo w/ Pembro. Part B:  
Durvalumab w/ Pembro or  
Placebo w/ Durvalumab)

Mechanism: TKI and Anti-  
PD-1 / Anti-PD-L1  
Coord: TBD  
PI: Dr. Park  
Accrual: 0/5

UCI 25-164: Divarasib  
+ Pembro vs Pembro +  
Pem + Carbo or  
Cisplatin

Mechanism: TKI +  
Immuno + Chemo  
Coord: TBD  
PI: Dr. Nagasaka  
Accrual: 0/5

2L

UCI 21-53 (Loxo Oncology,  
Inc. LOXO-RAS-20001

Mechanism: TKI  
Coord: Mindy Chen  
PI: Dr. Nagasaka  
Accrual: 9/12

UCI 25-162: BBO-  
8520(The ONKORAS-  
101

Mechanism: TKI  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5

UCI 24-157 (RMC-6236-301)  
RMC-6236 vs Docetaxel

Mechanism: TKI  
Coord: To be determined  
PI: Dr. Arter  
Accrual: 0/5

UCI 22-87 (RMC-6236  
Revolution Med)

Mechanism: TKI  
Coordinator: Jenny Choe  
PI: Dr. Arter  
Accrual: 43/50



KRAS MUTATIONS (Cont.)

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

G12C, G12V, G12D

1L

2L

UCI 25-163  
(TBBO11818-101)

Mechanism: TKI  
 Coord: TBD  
 PI: Dr. Arter  
 Accrual: 0/5

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation


NTRK 1-3

1L


2L



## ADVANCED/METASTATIC

 Open to Accrual


 Low Accruing

 Pending Activation

# TP53 Mutations



**ADVANCED/METASTATIC**

 Open to Accrual

 Low Accruing

 Pending Activation

ROS1

1L

2L


UCI 21-47 ( NVL-520 Nuvalent)

Mechanism: TKI  
Coord: Keagan Buttigieg  
PI: Dr. Nagasaka  
Accrual: 11/16

**ROS1 Mutations**



## Early Stage

 Open to Accrual

 Low Accruing

 Pending Activation

### UCI 24-196 (Nuvation)

Taletrectinib vs Placebo post  
complete resection

Mechanism: ROS1 inhibitor  
Coord: Stephanie Fernandez  
PI: Dr. Arter  
Accrual: 0/5



■ Open to Accrual

■ Low Accruing

■ Pending Activation

# Advanced / Metastatic

1L

UCI 24-83: CB-NK +  
Atezolizumab

Mechanism: PD-L1  
Coord: TBD  
PI: Dr. Villalona  
Accrual: 0/9

UCI 25-114: Ivonescimab vs  
Pembrolizumab (High PD-L1  
Expression (TPS> 50%))

Mechanism: PD-L1  
Coord: Richard Chang  
PI: Dr. Park  
Accrual: 0/5

UCI 24-195 (Seagen/Pfizer):  
PF-08046054/SGN-PDL1V

Mechanism: PD-L1  
Coord: Jenny Choe  
PI: Dr. Nagasaka  
Accrual: 0/5

2L


UCI 25-101 UCLA/Summit  
Therapeutics: Thymic  
Cancer (Ivonescimab)

Mechanism: PD-L1  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5

UCI 25-227 (Fortvita  
Biologics): IBI363 +/- SOC  
therapy

Mechanism: PD-L1  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5



 Open to Accrual

 Low Accruing

 Pending Activation


UCI 24-197 (TNG456  
Monotherapy & Combo w/  
Abemaciclib)

Mechanism:  
Coord: Cassie Smith  
PI: Dr. Park  
Accrual: 1/5

UCI 24-78 (AMG 193 Alone or  
Comb w/Other Therapies)

Mechanism:  
Coord: Cassie Smith  
PI: Dr. Villalona  
Accrual: 3/5



 Open to Accrual

 Low Accruing

 Pending Activation


UCI 24-138 (UCLA):  
Tarlutamab

Mechanism: BiTE molecule  
Coord: Cassie Smith  
PI: Dr. Park  
Accrual: 2/5


UCI 25-133: (ZG006)

Mechanism: BiTE molecule  
Coord: Jenny Choe  
PI: Dr. Arter  
Accrual: 2/5



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-194 (Plexium)

PLX-61639

Mechanism: SMARCA2

Degrader


Coord: TBD

PI: Dr. Villalona

Accrual: 0/5

# SMARCA4 Mutations



 Open to Accrual

 Low Accruing

 Pending Activation

Adjuvant

ADVANCED/METASTATIC

UCI 25-89 (IBI3009)


Mechanism: Recombinant Anti-DLL3  
Monoclonal Antibody-Camptothecin  
Derivative Conjugate for Injection

Coordinator: TBD  
PI: Dr. Arter

Accrual: 0/5



# Non-Treatment Studies

 Open to Accrual

 Low Accruing

 Pending Activation

**UCI 22-86: Gut Microbiome Study**

Mechanism: Fecal Collection  
Coord: Stephanie Fernandez  
PI: Dr. Nagasaka  
Accrual: 11/82

**UCI 24-118 (Keshava IIT): Lung Cancer Family Screening**

Mechanism: NA  
Coord: Stephanie Fernandez/  
Mindy Chen  
PI: Dr. Keshava  
Accrual: 44/1753

**UCI 25-179 (T. Waddington IIT)**  
Optical Coherence Tomography (OCT) w/ Robotic assisted bronch evaluate peripheral nodes

Mechanism: N/A  
CRC: TBD  
PI: Dr. Waddington  
Accrual: 0/5

**UCI 25-191 (Nagasaka IIT)**  
Mechanism: N/A  
CRC: TBD  
PI: Dr. Nagasaka  
Accrual: 0/25

**UCI 24-87 (Arter IIT): Methionine-Reduced Diet**

Mechanism: N/A  
CRC: TBD  
PI: Dr. Arter  
Accrual: 0/25

**UCI 23-155:**  
Chatbot for Online Support Groups to Treat Tobacco Addiction

Mechanism: N/A  
CRC: TBD  
PI: Dr. Pechmann  
Accrual: 0/126



■ Open to Accrual

■ Low Accruing

■ Pending Activation

# Advanced / Metastatic

1L

**UCI 24-113 (BMS-986482)**  
**Bristol-Myers Squibb**

Mechanism: PDL1  
 Coord: Natalie Arechiga  
 PI: Dr. Chow  
 Accrual: 5/10

2L

**UCI 24-08 (SPEDOX-6): Dr. Chow IIT**

Mechanism: SPE  
 Coord: Erin Palmer-Torrison  
 PI: Dr. Chow  
 Accrual: 8/67

**UCI 25-75 (CRN09682-191): Crinetics Pharmaceuticals**

Mechanism: NDC  
 Coord: Michelle Andrade  
 PI: Dr. Dayyani  
 Accrual: 0/15